Company overview

With more than 300 ongoing, worldwide clinical trials for the treatment of cancer and other severe, immune, inflammatory conditions, Celgene has a strong pipeline and an enormous commitment to innovative science. As dedicated as they are to clinical accomplishment, Celgene is equally committed to patient support. Their partnerships with patient groups and healthcare professionals have re-defined corporate social responsibility for the pharma industry and lain down the highest of standards as a benchmark. In the words of their CEO, Sol J Barer: "Our commitment to medical progress goes hand in hand with our pledge to patients."

While growing as an integrated and culturally diverse biopharmaceutical company, Celgene's patient-centric activities at local level go from strength to strength. Leading-edge, patient support programmes in the UK, other EU and non-EU countries, have clearly put patients first. Working in the UK, for example, with charities such as Myeloma UK and the Rarer Cancers Forum, their patient support programmes and innovative access schemes (such as for Revlimid) have been principled and transparent.